Glaukos Co. (NYSE:GKOS) Shares Sold by Braidwell LP

Braidwell LP lessened its stake in Glaukos Co. (NYSE:GKOS) by 37.2% during the third quarter, Holdings Channel reports. The firm owned 311,616 shares of the medical instruments supplier’s stock after selling 184,960 shares during the period. Braidwell LP’s holdings in Glaukos were worth $40,597,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in GKOS. Point72 Asset Management L.P. acquired a new position in Glaukos during the 2nd quarter valued at about $67,460,000. Primecap Management Co. CA lifted its stake in Glaukos by 43.9% during the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after purchasing an additional 372,180 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after purchasing an additional 246,322 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Glaukos by 47.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock valued at $83,609,000 after acquiring an additional 207,338 shares during the period. Finally, Driehaus Capital Management LLC raised its holdings in shares of Glaukos by 24.0% during the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock valued at $95,112,000 after acquiring an additional 155,653 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the topic of a number of recent analyst reports. BTIG Research upped their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday. StockNews.com upgraded shares of Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. Stifel Nicolaus upped their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Piper Sandler set a $140.00 price target on shares of Glaukos in a report on Thursday, October 17th. Finally, Needham & Company LLC increased their price target on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $135.45.

Insider Transactions at Glaukos

In other news, Director Gilbert H. Kliman sold 3,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now owns 32,336 shares in the company, valued at approximately $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total value of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is owned by insiders.

Glaukos Trading Up 1.4 %

GKOS stock opened at $142.69 on Friday. The business has a fifty day moving average of $133.81 and a 200-day moving average of $124.52. The company has a market cap of $7.87 billion, a P/E ratio of -47.25 and a beta of 1.02. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $59.58 and a twelve month high of $146.86.

Glaukos (NYSE:GKOS) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The firm had revenue of $96.70 million during the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The company’s revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.50) earnings per share. As a group, equities research analysts expect that Glaukos Co. will post -1.91 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.